Swee Du Soon, Quinton Richard
Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
Front Endocrinol (Lausanne). 2019 Feb 21;10:97. doi: 10.3389/fendo.2019.00097. eCollection 2019.
Congenital hypogonadotrophic hypogonadism (CHH) is a rare but important etiology of pubertal failure and infertility, resulting from impaired gonadotrophin-releasing hormone secretion or action. Despite the availability of effective hormonal therapies, the majority of men with CHH experience unsatisfactory outcomes, including chronic psychosocial and reproductive sequelae. Early detection and timely interventions are crucial to address the gaps in medical care and improve the outlook for these patients. In this paper, we review the clinical implications of missing minipuberty in CHH and therapeutic strategies that can modify the course of disease, as well as explore a targeted approach to identifying affected male infants by integrating clinical and biochemical data in the early postnatal months.
先天性低促性腺激素性性腺功能减退(CHH)是青春期发育障碍和不育症的一种罕见但重要的病因,由促性腺激素释放激素分泌或作用受损引起。尽管有有效的激素疗法,但大多数CHH男性患者的治疗效果并不理想,包括慢性心理社会和生殖后遗症。早期发现和及时干预对于弥补医疗差距和改善这些患者的预后至关重要。在本文中,我们回顾了CHH中婴儿期小青春期缺失的临床意义以及可改变疾病进程的治疗策略,并探讨了一种通过整合出生后早期几个月的临床和生化数据来识别受影响男婴的靶向方法。